Results 1 to 10 of about 5,152,763 (401)
European Journal of Surgical Oncology, 2023
The need for a common education and training track in surgical oncology across Europe has been emphasized. ESSO provides several hands-on courses for skills training and face-to-face discussions. The core curriculum provides a framework for the overall theoretical requirements in surgical oncology. The UEMS/EBSQ fellowship exam is designed to test core
Kjetil Søreide+4 more
openaire +6 more sources
The need for a common education and training track in surgical oncology across Europe has been emphasized. ESSO provides several hands-on courses for skills training and face-to-face discussions. The core curriculum provides a framework for the overall theoretical requirements in surgical oncology. The UEMS/EBSQ fellowship exam is designed to test core
Kjetil Søreide+4 more
openaire +6 more sources
Journal of Hematology & Oncology, 2022
Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of ...
Xuhui Tong+8 more
doaj +1 more source
Many types of human cells self-destruct to maintain biological homeostasis and defend the body against pathogenic substances. This process, called regulated cell death (RCD), is important for various biological activities, including the clearance of ...
Xuhui Tong+8 more
doaj +1 more source
Oncogenesis, 2022
Pancreatic ductal adenocarcinoma (PDAC) is a well-known lethal and heterogeneous disease. Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) is an important mutagenic driver that has seldom been investigated in PDAC. Therefore, this
Yunzhen Qian+13 more
doaj +1 more source
Pancreatic ductal adenocarcinoma (PDAC) is a well-known lethal and heterogeneous disease. Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) is an important mutagenic driver that has seldom been investigated in PDAC. Therefore, this
Yunzhen Qian+13 more
doaj +1 more source
World Journal of Surgical Oncology, 2021
Background Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC).
Yitao Gong+11 more
doaj +1 more source
Background Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC).
Yitao Gong+11 more
doaj +1 more source
Cancer Cell International, 2021
Background ALDOA is a glycolytic enzyme found mainly in developing embryos, adult muscle and various malignant tumours, including pancreatic tumours. Our previous study revealed that ALDOA, an oncogene, can promote the proliferation and metastasis of ...
Haidi Chen+11 more
doaj +1 more source
Background ALDOA is a glycolytic enzyme found mainly in developing embryos, adult muscle and various malignant tumours, including pancreatic tumours. Our previous study revealed that ALDOA, an oncogene, can promote the proliferation and metastasis of ...
Haidi Chen+11 more
doaj +1 more source
CA: A Cancer Journal for Clinicians, 1994
Pancreatic cancer is a devastating disease for the patient and presents challenging diagnostic and management problems for the physician. A range of serologic and radiologic studies are available for evaluation and staging of this disease. However, invasive studies, including laparotomy, are often necessary to establish the diagnosis and resectability.
Michel G. Sarr+3 more
openaire +3 more sources
Pancreatic cancer is a devastating disease for the patient and presents challenging diagnostic and management problems for the physician. A range of serologic and radiologic studies are available for evaluation and staging of this disease. However, invasive studies, including laparotomy, are often necessary to establish the diagnosis and resectability.
Michel G. Sarr+3 more
openaire +3 more sources
Trials, 2023
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. Radical surgical resection offers the only potential cure. There is increasing agreement that radical antegrade modular pancreatosplenectomy (RAMPS) may benefit ...
Jialin Li+11 more
doaj +1 more source
Background Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy. Radical surgical resection offers the only potential cure. There is increasing agreement that radical antegrade modular pancreatosplenectomy (RAMPS) may benefit ...
Jialin Li+11 more
doaj +1 more source
Cancer Control, 2020
Lymphatic metastasis is a major determinant of the outcome of resected pancreatic cancer. Gemcitabine-based adjuvant chemotherapy can improve the outcome of resected pancreatic cancer.
Chen Liu MD, PhD+10 more
doaj +1 more source
Lymphatic metastasis is a major determinant of the outcome of resected pancreatic cancer. Gemcitabine-based adjuvant chemotherapy can improve the outcome of resected pancreatic cancer.
Chen Liu MD, PhD+10 more
doaj +1 more source